Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - mesna - injection, solution, concentrate - mesna 400 mg/4 ml

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio libra, s.a. - ifosfamida - ifosfamida....1.00 g

Israel - English - Ministry of Health

mbi pharma ltd., israel - ifosfamide - solution for infusion - ifosfamide 2 g / 50 ml - ifosfamide - • testicular tumours for combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.• cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.• breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.• non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.• small-cell lung cancerfor combination chemotherapy.• soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy.• ewing’s sarcomafor combination chemotherapy after failure of primary cytostatic therapy.• non-hodgkin’s lymphomafor combination chemotherapy in patients with highly malignant non-hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. for combination therapy of patients with recurrent tumours.• hodgkin’s diseasefor the treatment of patients with primary progressive forms and early relapse of hodgkin’s disease (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radiochemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the mine protocol.

Israel - English - Ministry of Health

mbi pharma ltd., israel - ifosfamide - concentrate for solution for infusion - ifosfamide 5 g / 25 ml - ifosfamide - • testicular tumours for combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.• cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.• breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.• non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.• small-cell lung cancerfor combination chemotherapy.• soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy.• ewing’s sarcomafor combination chemotherapy after failure of primary cytostatic therapy.• non-hodgkin’s lymphomafor combination chemotherapy in patients with highly malignant non-hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. for combination therapy of patients with recurrent tumours.• hodgkin’s diseasefor the treatment of patients with primary progressive forms and early relapse of hodgkin’s disease (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radiochemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the mine protocol.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 600 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; maize starch; povidone; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; simethicone - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects section of the cyclophosphamide and ifosfamide product information)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 400 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; maize starch; povidone; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; simethicone - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects section of the cyclophosphamide and ifosfamide product information)

Israel - English - Ministry of Health

megapharm ltd - mesna - solution for injection - mesna 400 mg/vial - mesna - prevention of urinary passage toxicity of oxazaphosphorines (ifosfamide ,cyclophosphamide, trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous ifosfamide, cyclophosphamide or trofosamide , urinary passage diseases in anamnesis.

Kenya - English - Pharmacy and Poisons Board

getwell pharmaceuticals ltd 474, udyog vihar, phase-v, gurugram- 122016, - ifosfamide usp and mesna bp - powder for injection - 2gm of sterile ifosfamide usp and mesna bp… - combinations of antineoplastic agents

Israel - English - Ministry of Health

megapharm ltd - ifosfamide - powder for solution for inj/inf - ifosfamide 1 g/vial - ifosfamide - testicular tumourfor combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.small-cell lung cancerfor combination chemotherapy.soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy.ewing’s sarcomafor combination chemotherapy after failure of primary cytostatic therapy.non-hodgkin’s lymphomafor combination chemotherapy in patients with highly malignant non-hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. for combination therapy of patients with recurrent tumours.hodgkin’s lymphomafor the treatment of patients with primary progressive forms and early relapse of hodgkin’s lymphoma (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radio-chemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the mine protocol.

Israel - English - Ministry of Health

megapharm ltd - ifosfamide - powder for solution for inj/inf - ifosfamide 2 g/vial - ifosfamide - testicular tumourfor combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.small-cell lung cancerfor combination chemotherapy.soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy.ewing’s sarcomafor combination chemotherapy after failure of primary cytostatic therapy.non-hodgkin’s lymphomafor combination chemotherapy in patients with highly malignant non-hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. for combination therapy of patients with recurrent tumours.hodgkin’s lymphomafor the treatment of patients with primary progressive forms and early relapse of hodgkin’s lymphoma (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radio-chemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the mine protocol.